Intensity Therapeutics INTS
NASDAQ INTS
$3.51 +0.23 (+7.01%)
As of: Oct 21, 2026 · 10:37 AM EDT

Intensity Therapeutics (INTS) Minority Interest (2022)

Updated

Intensity Therapeutics (INTS) posted Minority Interest of $10 million for Q4 2022.

Analysis

Intensity Therapeutics (INTS) Minority Interest (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,131.65 Bn 1,100.24 Bn 19.71 Bn
2 Johnson & Johnson 615.89 Bn 534.41 Bn 17.26 Bn
3 AbbVie 505.03 Bn 478.14 Bn 12.70 Bn
4 Merck 368.78 Bn 323.16 Bn 12.21 Bn
5 Novartis Ag 298.66 Bn 262.65 Bn 11.24 Bn
6 Astrazeneca 262.09 Bn 235.78 Bn 12.86 Bn
7 Amgen 236.57 Bn 191.97 Bn 7.24 Bn
8 Gilead Sciences 191.05 Bn 165.25 Bn 6.22 Bn
9 Pfizer 170.60 Bn 117.25 Bn 10.94 Bn
10 Intensity Therapeutics 9.50 Mn -29.26 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 10.00 Mn
API Access

Intensity Therapeutics Minority Interest API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=minority-interest&ticker=INTS&period=max&api_key=YOUR_API_KEY